Choose a maintenance treatment with…

Unrivalled long-term follow-up efficacy data:

  • 11% of patients in Study 19 on LYNPARZA capsules have remained on treatment for 6 years5

Proven efficacy:

  • Study 19 demonstrates that LYNPARZA may extend your patients’ PFS, regardless of their BRCA status6

A generally well-tolerated safety profile:

  • 94% of patients in Study 19 and 89% in SOLO-2 were able to continue on treatment until disease progression4,8
  • SOLO-2 saw only 25% of patients have their LYNPARZA (tablets) dose reduced4